Create an international first-class Synthetic biology enterprise

Company Profile

Fully-automated pharmaceutical company

Total assets over 300 million USD

Full manufacturing chain from pharmaceutical intermediates,APIs to FPFs

Major produtcts FDA and EDQM approved

Products export to over 50 countries

Manufacturing Capacity

540000㎡ fully-automated workshops

1200+ professionals(14% R&D personnel)

Annual production capacity:

       10000 tons of APIs & intermediates

        5 billion of OSD

 600 million of powder for injection


More »
APIs and Intermediates
Final Dosage Forms
R&D and Innovation
Group Market Map

After nearly a decade of experience, Shuangyan's sales performance has grown rapidly year by year, and its current sales have exceeded 1 billion yuan.

Shuangyan Group has actively expanded its global sales network over the years, with products selling well in over 50 countries and regions such as Europe, the United States, the Middle East, Africa, and Southeast Asia. Actively participate in the joint construction of the "the Belt and Road", establish trade relations with many countries along the "the Belt and Road", and constantly expand cooperation channels.

MORE »
  • 2 billion+

    sales volume

  • 50+

    Best selling in countries and regions

Enterprise Chronicles
  • 2004
    Shanxi Xinbaoyuan Pharmaceutical was established

    Professional production of local anesthesia and antitussive raw materials

  • 2013
    Production of bismuth agent

    Introducing the original research "bismuth agent series" raw materials and preparation products and putting them into production, becoming the first domestic enterprise to complete the industrial chain of bismuth preparation products

  • 2014
    Absorb and merge Spark Pharmaceuticals

    Introducing medication for children, respiratory system, and cardiovascular systems; Enrich existing product lines

  • 2015
    Biological enzyme pharmaceutical intermediates

    Commercialized production of biological enzyme series production line and pharmaceutical intermediate D p-hydroxy Phenylglycine series production line

  • 2016
    digestive system

    The introduction of raw materials and preparations of trimebutine maleate has expanded the distribution of digestive system drugs

  • 2022
    Shanxi Shuangyan Health Industry Group Established

    Shanxi Shuangyan Biotechnology: Operating Biological Enzyme Series

    Production of products, D-p-hydroxy Phenylglycine series intermediates

    Shanxi Shuangyan Pharmaceutical: engaged in the production of pharmaceutical raw materials and oral solid preparations

    Shanghai Banglin: front-end research and development of Synthetic biology and high-end preparation development

  • 2023
    New Shuangyan Biopharmaceutical Industrial Park

    The first phase covers an area of over 500 acres, with a planned investment of 1.5 billion yuan and 17 new workshops to further expand production capacity

  • 2024
    Shuangyan Biopharmaceutical Industrial Park

    All facilities have reached full operational capacity and achieved optimized production efficiency

  • 2025

News Media Center